OyeCricket.com

OyeCricket.com With Business-News-Today.com, you don’t just follow the news. You get ahead of it.

Welcome to Business-News-Today.com — your dedicated source for business news today, real-time financial market updates, and deep-dive global market analysis from the world’s most important economies. Business news today, financial market updates & global market analysis
Welcome to Business-News-Today.com — your dedicated source for business news today, real-time financial market updates, and deep-

dive global market analysis from the world’s most important economies. Whether you’re an investor, entrepreneur, or market analyst, we bring you fast, accurate, and actionable coverage across the U.S., India, Europe, Asia, Australia, and Canada—bringing you timely updates from the world’s most influential financial markets. From breaking headlines and stock market performance today to sector-specific developments and economic indicators, we keep you updated on what’s moving the markets in real time. Our mission is to offer expert-curated insights that connect global business events with strategic investment decisions — all mapped to key financial market trends shaping the day.

Accuray (NASDAQ: ARAY) bets on personalized cancer care with University of Wisconsin research alliance $ARAY ...
17/05/2026

Accuray (NASDAQ: ARAY) bets on personalized cancer care with University of Wisconsin research alliance $ARAY

Accuray has deep radiotherapy science but weak market trust. Its Wisconsin pact tests whether innovation can still reset the ARAY story.

Babcock (LSE: BAB) absorbs Type 31 charge but keeps FY27 outlook intact $BAB.L
17/05/2026

Babcock (LSE: BAB) absorbs Type 31 charge but keeps FY27 outlook intact $BAB.L

Babcock’s Type 31 charge hurts profits, but cash flow and buybacks keep the turnaround alive. The ex*****on risk now moves to FY27.

Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still ha...
17/05/2026

Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
$REGN

Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.

EPACK Prefab (EPACKPEB) rebounds after FY26 earnings, but can prefab capacity expansion sustain investor confidence? ...
17/05/2026

EPACK Prefab (EPACKPEB) rebounds after FY26 earnings, but can prefab capacity expansion sustain investor confidence?

EPACKPEB has growth, cash and orders. The bigger test is whether prefab capacity can turn India’s speed problem into durable earnings.

AI needs data centres, but capital needs liquidity. DayOne’s planned dual listing could test Singapore’s Nasdaq bridge a...
17/05/2026

AI needs data centres, but capital needs liquidity. DayOne’s planned dual listing could test Singapore’s Nasdaq bridge at scale. $GDS

AI needs data centres, but capital needs liquidity. DayOne’s planned dual listing could test Singapore’s Nasdaq bridge at scale.

Prudential wants control in India, but must dilute ICICI Prudential Life. See why the Bharti Life deal tests control ver...
17/05/2026

Prudential wants control in India, but must dilute ICICI Prudential Life. See why the Bharti Life deal tests control versus legacy scale. $PRU

Prudential wants control in India, but must dilute ICICI Prudential Life. See why the Bharti Life deal tests control versus legacy scale.

Australian Oil Company (ASX:AOK) pushes Surat Basin oil and gas restart as first Emu Apple revenue nears $AOK ...
17/05/2026

Australian Oil Company (ASX:AOK) pushes Surat Basin oil and gas restart as first Emu Apple revenue nears $AOK

Australian Oil Company has first oil revenue, but ASX:AOK still needs production scale. The Surat Basin test is now about ex*****on.

Munich Re (ETR: MUV2) trades 23% below 52-week high as reinsurance pricing softens into hurricane season $MUV2 ...
17/05/2026

Munich Re (ETR: MUV2) trades 23% below 52-week high as reinsurance pricing softens into hurricane season $MUV2

Munich Re beat Q1 by 57% and reaffirmed €6.3bn guidance. The stock is down 23%. The real question is whether softening renewal prices break the Ambition 2030 thesis.

Leidos (NYSE: LDOS) stock faces defence re-rating test as hypersonics and low-cost missile deals reshape growth story $L...
17/05/2026

Leidos (NYSE: LDOS) stock faces defence re-rating test as hypersonics and low-cost missile deals reshape growth story $LDOS

Leidos has fresh missile catalysts, but LDOS still trades far below its high. The real test is whether production scale changes the story.

SpaceX may test IPO history. BlackRock’s reported billions could decide whether private-market hype survives public scru...
17/05/2026

SpaceX may test IPO history. BlackRock’s reported billions could decide whether private-market hype survives public scrutiny. $BLK

SpaceX may test IPO history. BlackRock’s reported billions could decide whether private-market hype survives public scrutiny.

Address

Hyderabad

Telephone

+917032378517

Website

Alerts

Be the first to know and let us send you an email when OyeCricket.com posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to OyeCricket.com:

Shortcuts

Share

Category